Infectious Diseases News

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of Liver (EASL) Congress in Barcelona, Spain, demonstrating the first clinical evidence of epigenetic silencing in hepatitis B virus (HBV). The oral presentation was delivered by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on HBV. The phase 1b/2a clinical trial evaluated the safety an...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250...

WILMINGTON, Del.--(BUSINESS WIRE)--Residents of Delaware County will soon have a new option for around-the-clock emergency and inpatient care closer to home. In early June, ChristianaCare will open ChristianaCare Hospital, Aston, a neighborhood hospital designed to expand access to care in a growing region with increasing health care needs. Download photos. The hospital is expected to care for approximately 15,000 patients each year, or about 40 per day, and will provide 24/7 emergency care, in...

PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The European Association for the Study of the Liver) in Barcelona, Spain, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced HBV-specific immune activation, restoration, and continued HBsAg declines, without...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma commits to invest in GHIC's Global Health Security Fund to accelerate innovations addressing pandemic preparedness and AMR....

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s...

SEATTLE--(BUSINESS WIRE)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo. Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI’s proprietary SLA-SE adjuvant. The acquisition underscores the growing recogni...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live w...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an...